Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Cinryze Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Cinryze (C1 esterase inhibitor [human]) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Advantage Part B prior authorization and coverage for Cinryze used for routine prophylaxis against hereditary angioedema attacks in adults, adolescents, and children age 6 years and older.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyCinryze (C1 esterase inhibitor [human]) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses to treatment with each Cinryze prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 6+Minimum patient age
    2 yearsCoverage duration
    J0598Covered HCPCS code
    10 unitsBilling unit
    None

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Explicit exclusions

    Covered Indication

    FDA-Approved Covered Use

    Covered for the FDA-approved indication when the patient has hereditary angioedema and is receiving routine prophylaxis against angioedema attacks.

    Covered indication

    • Eligible age: Patient is an adult, adolescent, or pediatric patient age 6 years or older.age >= 6 years

    Initial Cinryze Therapy

    Initial Cinryze Therapy

    Initial coverage is available for the FDA-approved indication with required supporting medical records.

    Initial therapy requirements: Use is for routine prophylaxis against angioedema attacks in a patient with hereditary angioedema who is age 6 years or older.age >= 6 years

    Medical records must document prior therapies and responses to treatment.

    Covered Codes

    Covered HCPCS CodesHCPCSCovered
    J0598Cinryze (C-1 esterase inhibitor [human])

    Authorization and Documentation

    Prior Authorization

    Submit prior authorization for Cinryze

    Prior authorization applies to Cinryze requests. Support the request with medical records documenting the patient's prior therapies and responses to treatment.

    Documentation Required

    Include required clinical documentation

    Submit medical records supporting the request, including documentation of prior therapies and responses to treatment.

    • Document the therapies previously attempted.
    • Include the patient’s responses to those treatments.

    Cinryze Overview

    Cinryze (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). Coverage applies to adults, adolescents, and pediatric patients 6 years of age and older when Cinryze is used for this FDA-approved indication.

    Key Condition

    Hereditary Angioedema (HAE)
    ConditionHereditary angioedema (HAE)
    Covered useRoutine prophylaxis against angioedema attacks
    Eligible patientsAdults, adolescents, and pediatric patients 6 years of age and older
    Covered medicationCinryze (C1 esterase inhibitor [human])
    Policy Summary
    PayerGold Coast Health Plan
    PolicyCinryze (C1 esterase inhibitor [human]) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses to treatment with each Cinryze prior authorization request.
    SourceLink
    On This Page
    Covered IndicationInitial Cinryze TherapyCovered CodesAuthorization and DocumentationCinryze OverviewKey Condition
    Denial Risk

    Avoid missing medical records

    The request must include medical records supporting the request, including documentation of prior therapies and responses to treatment. Requests without this supporting documentation may not satisfy the coverage requirements.